Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Mersana Therapeutics, Inc. is not a good value stock. Mersana Therapeutics, Inc. is not a good growth stock. Mersana Therapeutics, Inc. is a mediocre stock to choose.

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to...

News

ClariVest Asset Management LLC Has $1.01 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Ticker Report ClariVest Asset Management LLC boosted its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 6.1% in the second quarter, according to the company in its most recent 13F...\n more…

Citigroup Lowers Mersana Therapeutics (NASDAQ:MRSN) Price Target to $5.00

Zolmax Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) had its price target lowered by research analysts at Citigroup from $6.00 to $5.00 in a research report issued to clients and investors on...\n more…

Mersana Therapeutics (NASDAQ:MRSN) Price Target Lowered to $5.00 at Citigroup

Ticker Report Mersana Therapeutics (NASDAQ:MRSN - Free Report) had its price objective cut by Citigroup from $6.00 to $5.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They...\n more…

Mersana Therapeutics price target lowered by $1 at Citi, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ticker Report Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are presently covering the stock...\n more…

Mersana Therapeutics (NASDAQ:MRSN) Releases Earnings Results, Misses Expectations By $0.02 EPS

Ticker Report Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of...\n more…